Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ISRCTN37514492) titled 'A long-term extension (LTE) study of guselkumab in pediatric participants' on Feb. 3.
Study Type: Interventional
Study Design:
Allocation: Non-randomized controlled trial
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Treatment
Primary Sponsor: Janssen-Cilag International NV
Condition:
Moderately to severely active ulcerative colitis (UC), moderately to severely active Crohn's disease (CD), Juvenile psoriatic arthritis (jPsA)
Digestive System
Intervention:
Long-term safety study for guselkumab. All patients will receive the active drug, open-label, with no randomisation. ...